One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Catalent logo
Catalent CTLT
report update icon

Quarterly report 2025-Q1
added 05-16-2026

Catalent Cash Flow 2024-2011 | CTLT

Brief overview of Catalent's cash movements

Cash flows are assessed across five available annual periods spanning 2020 to 2024.

Cash from operations fell 39.1%, from $440 million to $268 million. The direction warrants attention.

Each of the five years produced positive cash from operations, indicating stable cash generation.

Only 6.1% of revenue now converts into operating cash flow versus 14.2% previously.

Working capital needs increased $293 million, or 6.7% of sales. This may restrain cash conversion.

Conclusion

There is no unconditional cash flow signal for Catalent. Repeatability of OCF and the quality of its use remain important.

Annual Cash Flow Catalent

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

268 M 254 M 439 M 433 M 440 M 248 M 374 M 300 M 155 M 172 M 178 M 138 M 87.9 M -

Depreciation & Amortization

489 M 422 M 378 M 289 M 254 M 229 M 190 M 146 M 141 M 141 M 143 M 152 M 130 M -

Accounts Payables

361 M 424 M 421 M 385 M 321 M 256 M 192 M 163 M 144 M 128 M 148 M 151 M - -

Accounts Receivables

921 M 1 B 1.05 B 1.01 B 838 M 693 M 556 M 489 M 415 M 372 M 404 M 358 M - -

Total Inventories

574 M 777 M 702 M 563 M 324 M 257 M 209 M 185 M 155 M 133 M 135 M 125 M - -

All numbers in USD currency

Quarterly Cash Flow Catalent

2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

61 M 54 M 42 M -70 M - 58 M 122 M -92 M - -92 M 122 M 370 M 232 M 163 M 224 M 299 M 224 M 150 M 146 M 25.2 M - 160 M 84.5 M 41.2 M - 271 M 176 M 83.7 M - 199 M 96 M 48.3 M - 121 M 71.5 M 48.3 M - 94.7 M 400 K 44.9 M - -39.8 M 400 K -39.8 M - 25.2 M - - - - - - - - - -

Depreciation & Amortization

113 M 359 M 233 M 112 M 121 M 308 M 202 M 99 M 103 M 99 M 202 M 278 M 179 M 81 M 140 M 216 M 140 M 69 M 122 M 60.6 M 61.9 M 174 M 108 M 52.9 M 54.6 M 138 M 85.8 M 39 M 46.8 M 108 M 71.3 M 35.8 M 35.5 M 106 M 70.7 M 35.8 M 35.2 M 105 M 70.2 M 35.5 M 35.2 M 35 M 70.2 M 35 M 37.3 M 36.5 M - - - - - - - - - -

Accounts Payables

375 M 377 M 407 M 367 M 407 M 394 M 367 M 379 M 367 M 379 M 421 M 401 M 363 M 363 M 385 M 329 M 357 M 276 M 243 M 214 M 243 M 202 M 184 M 180 M 184 M 183 M 164 M 167 M 164 M 138 M 128 M 146 M 128 M 135 M 128 M 144 M 128 M 121 M 118 M 127 M 118 M 117 M 148 M 148 M - - 151 M - - - - - - - - -

Accounts Receivables

760 M 875 M 843 M 830 M 843 M 1.05 B 916 M 989 M 916 M 989 M 1.05 B 932 M 871 M 831 M 1.01 B 701 M 772 M 699 M 681 M 648 M 681 M 584 M 551 M 503 M 551 M 507 M 428 M 410 M 428 M 403 M 366 M 376 M 366 M 344 M 332 M 415 M 332 M 332 M 336 M 308 M 336 M 332 M 404 M 404 M - - 358 M - - - - - - - - -

Total Inventories

553 M 742 M 775 M 796 M 775 M 744 M 818 M 732 M 818 M 732 M 702 M 676 M 688 M 622 M 563 M 384 M 461 M 297 M 250 M 251 M 250 M 247 M 235 M 236 M 235 M 224 M 213 M 194 M 213 M 194 M 170 M 178 M 170 M 168 M 159 M 155 M 159 M 142 M 144 M 151 M 144 M 142 M 135 M 135 M - - 125 M - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Catalent, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Drug manufacturers sector

Issuer Price % 24h Market Cap Country
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
- - $ 2.06 B franceFrance
Pacira BioSciences Pacira BioSciences
PCRX
$ 36.48 0.04 % $ 1.63 B usaUSA
Perrigo Company plc Perrigo Company plc
PRGO
$ 16.83 -0.71 % $ 2.33 B usaUSA
Evoke Pharma Evoke Pharma
EVOK
- - $ 36.6 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 7.19 2.35 % $ 629 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 1.4 -0.36 % $ 361 M canadaCanada
Tilray Tilray
TLRY
$ 2.66 -6.84 % $ 297 M canadaCanada
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Veru Veru
VERU
$ 2.12 -3.2 % $ 31.1 M usaUSA
Viatris Viatris
VTRS
$ 20.86 1.81 % $ 23.9 B usaUSA
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
cbdMD cbdMD
YCBD
$ 0.39 1.86 % $ 1.57 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
China Pharma Holdings China Pharma Holdings
CPHI
$ 0.55 -2.64 % $ 2.36 M chinaChina
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Zynerba Pharmaceuticals Zynerba Pharmaceuticals
ZYNE
- - $ 55.5 M usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 0.59 -5.37 % $ 176 M canadaCanada
Aurora Cannabis Aurora Cannabis
ACB
$ 5.11 -1.07 % $ 280 M canadaCanada
Harrow Health Harrow Health
HROW
$ 30.4 10.67 % $ 1.12 B usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 5.39 0.37 % $ 80.1 M usaUSA
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 4.24 2.42 % $ 167 M usaUSA
Emergent BioSolutions Emergent BioSolutions
EBS
$ 6.04 -0.98 % $ 323 M usaUSA
Cronos Group Cronos Group
CRON
$ 3.43 -3.25 % $ 1.32 B canadaCanada
Evolus Evolus
EOLS
$ 6.81 -2.51 % $ 439 M usaUSA
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 0.96 5.83 % $ 122 M usaUSA
Bausch Health Companies Bausch Health Companies
BHC
$ 8.33 -0.83 % $ 3.09 B canadaCanada
OrganiGram Holdings OrganiGram Holdings
OGI
$ 0.85 -2.69 % $ 81 M canadaCanada
Rockwell Medical Rockwell Medical
RMTI
$ 7.35 -2.26 % $ 264 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 3.54 1.14 % $ 177 M usaUSA
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 1.12 -0.88 % $ 1.89 M usaUSA
TherapeuticsMD TherapeuticsMD
TXMD
$ 1.74 2.96 % $ 20.1 M usaUSA
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
- - $ 150 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
ProPhase Labs ProPhase Labs
PRPH
- - $ 5.07 M usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
- -0.21 % $ 98 M usaUSA